2026 ICD-10-CM Diagnosis Code T38.992APoisoning by other hormone antagonists, intentional self-harm, initial encounter

ICD-10-CM Codes›S00–T88›T36-T50›T38

ICD-10-CM T38.992A
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

T38.992A is a billable ICD-10-CM diagnosis code for poisoning by other hormone antagonists, intentional self-harm, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. Coders also document this condition as estrogen antagonist overdose. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under External cause codes: intent of injury, self-harm; External cause codes: poisoning by drug; and Poisoning by drugs, initial encounter.

Code Identity

ICD-10-CM Code
T38.992A
Billable Status
Yes — Valid for Submission
Code Describes
Poisoning by other hormone antagonists, intentional self-harm, initial encounter
Short Description
Poisoning by oth hormone antagonists, self-harm, init
Parent Code
T38.992
Poisoning by other hormone antagonists, intentional self-harm

Code Classification

ChapterS00–T88Injury, poisoning and certain other consequences of external causes
SectionT36-T50Poisoning by, adverse effect of and underdosing of drugs, medicaments and biological substances
CategoryT38Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified
This CodeT38.992APoisoning by other hormone antagonists, intentional self-harm, initial encounter

Approximate SynonymsGuidance

Alternate terms and clinical phrases that map to this code.

  • Estrogen antagonist overdose
  • Intentional poisoning caused by corticosteroid and/or corticosteroid derivative
  • Intentional trilostane overdose
  • Intentional trilostane poisoning
  • Trilostane overdose
  • Trilostane poisoning

Coding GuidelinesGuidance

When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined). If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.

The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of hormones and their synthetic substitutes and antagonists, not elsewhere classified (T38). Use the following options for the applicable episode of care:

  • A - initial encounter
  • D - subsequent encounter
  • S - sequela

Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR EXT021
External cause codes: intent of injury, self-harm
Default principal diagnosis: inpatient No · outpatient No
CCSR EXT014
External cause codes: poisoning by drug
Default principal diagnosis: inpatient No · outpatient No
CCSR INJ022
Poisoning by drugs, initial encounter
Default principal diagnosis: inpatient No · outpatient No
CCSR MBD012
Suicidal ideation/attempt/intentional self-harm
Default principal diagnosis: inpatient Yes · outpatient Yes

Clinical InformationClinical

  • Octreotide

    a potent, long-acting synthetic somatostatin octapeptide analog that inhibits secretion of growth hormone and is used to treat hormone-secreting tumors; diabetes mellitus; hypotension, orthostatic; hyperinsulinism; hypergastrinemia; and small bowel fistula.

  • Receptors, Somatostatin

    cell surface proteins that bind somatostatin and trigger intracellular changes which influence the behavior of cells. somatostatin is a hypothalamic hormone, a pancreatic hormone, and a central and peripheral neurotransmitter. activated somatostatin receptors on pituitary cells inhibit the release of growth hormone; those on endocrine and gastrointestinal cells regulate the absorption and utilization of nutrients; and those on neurons mediate somatostatin's role as a neurotransmitter.

  • Somatostatin

    a 14-amino acid peptide named for its ability to inhibit pituitary growth hormone release, also called somatotropin release-inhibiting factor. it is expressed in the central and peripheral nervous systems, the gut, and other organs. srif can also inhibit the release of thyroid-stimulating hormone; prolactin; insulin; and glucagon besides acting as a neurotransmitter and neuromodulator. in a number of species including humans, there is an additional form of somatostatin, srif-28 with a 14-amino acid extension at the n-terminal.

  • Somatostatin-28

    a 28-amino acid peptide with the same biological activities of somatostatin-14 but with a 14-amino acid extension at the n-terminal. srif-28 is the major form of somatostatin in the gastrointestinal tract.

  • Somatostatinoma

    a somatostatin-secreting tumor derived from the pancreatic delta cells (somatostatin-secreting cells). it is also found in the intestine. somatostatinomas are associated with diabetes mellitus; cholelithiasis; steatorrhea; and hypochlorhydria. the majority of somatostatinomas have the potential for metastasis.

  • Somatostatin-Secreting Cells

    endocrine cells found throughout the gastrointestinal tract and in islets of the pancreas. d cells secrete somatostatin that acts in both an endocrine and paracrine manner. somatostatin acts on a variety of tissues including the pituitary gland; gastrointestinal tract; pancreas; and kidney by inhibiting the release of hormones, such as growth hormone; gastrin; insulin; and renin.

Table of Drugs and ChemicalsClinical

Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.

SubstanceAccidentalSelf-harmAssaultUndeter­minedAdverse
Effect		Under­dosing
OctreotideT38.991T38.992T38.993T38.994T38.995T38.996
SomatostatinT38.991T38.992T38.993T38.994T38.995T38.996
TrilostaneT38.991T38.992T38.993T38.994T38.995T38.996

Patient EducationClinical

Hormones

Hormones are your body's chemical messengers. They travel in your bloodstream to tissues or organs. They work slowly, over time, and affect many different processes, including:

Read the full article at MedlinePlus

Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.

Convert T38.992A to ICD-9-CMHistory

The closest ICD-9-CM equivalents under the General Equivalence Mappings.

ICD-9-CM
962.9 Poisoning hormon NEC/NOS
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.
ICD-9-CM
E950.4 Poison-drug/medicin NEC
ApproximateCombination The match is approximate, and more than one code can be needed to describe the source diagnosis. Confirm with contextual judgment.

Code HistoryHistory

FY 2016AddedAdded to the ICD-10-CM code setEffective October 1, 2015, the first year of ICD-10-CM.
FY 2017–2025No changes
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About T38.992AOverview

Is T38.992A a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report poisoning by other hormone antagonists, intentional self-harm, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

What does the 7th character A in T38.992A mean?

The final character A marks the initial encounter: use it while the patient is receiving active treatment for poisoning by other hormone antagonists, intentional self-harm, such as an emergency visit or first evaluation.

What MS-DRG does T38.992A group to?

When poisoning by other hormone antagonists, intentional self-harm, initial encounter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.

What is the ICD-9 equivalent of T38.992A?

Under the General Equivalence Mappings, poisoning by other hormone antagonists, intentional self-harm, initial encounter converts to ICD-9-CM 962.9 (poisoning hormon NEC/NOS) and E950.4 (poison-drug/medicin NEC). The mapping is approximate, so confirm the match fits the documentation.

Footnotes

[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.